24 junio, 2021

RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study

THE BAJA POSTNEWSROOMSOURCE: https://prnmedia.prnewswire.com/ The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more …